SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)-A multicenter phase II trial.

被引：0
|
作者：
Mauti, Laetitia A.
Finazzi, Tobias
Holer, Lisa
Bettini, Adrienne
Konig, David
Fruh, Martin
Haefliger, Simon
Addeo, Alfredo
Mark, Michael Thomas
Buess, Martin
Froesch, Patrizia
Janthur, Wolf Dieter
Waibel, Christine
Ackermann, Christoph J.
Dorn, Patrick
Scheibe, Bernhard
Pless, Miklos
Guckenberger, Matthias
Prince, Spasenija Savic
Rothschild, Sacha
机构：
[1] Kantonsspital Winterthur, Dept Oncol, Winterthur, Switzerland
[2] Univ Basel Hosp, Clin Radiotherapy & Radiat Oncol, Basel, Switzerland
[3] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland
[4] HFR Hop Fribourgeois, Dept Oncol, Fribourg, Switzerland
[5] Univ Basel Hosp, Dept Med Oncol, Basel, Switzerland
[6] Univ Basel Hosp, Ctr Comprehens Canc, Basel, Switzerland
[7] Kantonsspital St Gallen, Dept Oncol Hematol, St Gallen, Switzerland
[8] Univ Bern, Inselspital, Bern Univ Hosp, Dept Med Oncol, Bern, Switzerland
[9] Univ Hosp HUG, Dept Oncol, Geneva, Switzerland
[10] Kantonsspital Graubuenden, Div Oncol Hematol, Chur, Switzerland
[11] St Claraspital Basel, Dept Oncol, Basel, Switzerland
[12] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[13] Kantonsspital Aarau, Dept Oncol Hematol, Aarau, Switzerland
[14] Kantonsspital Baden, Dept Oncol Hematol, Baden, Switzerland
[15] Spital Thun, Dept Oncol, Thun, Switzerland
[16] Univ Bern, Bern Univ Hosp, Inselspital, Dept Thorac Surg, Bern, Switzerland
[17] Univ Zurich Hosp, Dept Radiat Oncol, Zurich, Switzerland
[18] Univ Hosp Basel, Inst Med Genet & Pathol, Pathol, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8547
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC. Surgical Interim Analysis
    Dorn, P.
    Holer, L.
    Lardinois, D.
    Dutly, A.
    Karenovics, W.
    Habicht, J.
    Lutz, J. A.
    Gelpke, H.
    Opitz, I.
    Haefliger, S.
    Konig, D.
    Fruh, M.
    Addeo, A.
    Muhll-Schill, C. Vonder
    Bettini, A.
    Scheibe, B.
    Prince, S. Savic
    Guckenberger, M.
    Finazzi, T.
    Rothschild, S. I.
    Mauti, L. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S139 - S140
  • [2] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)-A multicenter single-arm phase II trial.
    Rothschild, Sacha
    Zippelius, Alfred
    Eboulet, Eric, I
    Savic, Spasenija
    Betticher, Daniel C.
    Bettini, Adrienne
    Frueh, Martin
    Joerger, Markus
    Britschgi, Christian
    Peters, Solange
    Mark, Michael Thomas
    Ochsenbein, Adrian
    Janthur, Wolf Dieter
    Waibel, Christine
    Mach, Nicolas
    Gonzalez, Michel
    Froesch, Patrizia
    Godar, Gilles
    Rusterholz, Corinne
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) - A multicenter single-arm phase II trial
    Rothschild, S. I.
    Zippelius, A.
    Eboulet, E. I.
    Prince, S. Savic
    Betticher, D.
    Bettini, A.
    Fruh, M.
    Joerger, M.
    Britschgi, C.
    Peters, S.
    Mark, M. T.
    Ochsenbein, A. F.
    Janthur, W-D.
    Waibel, C.
    Mach, N.
    Gonzalez, M.
    Froesch, P. R.
    Godar, G.
    Rusterholz, C.
    Pless, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S803 - S804
  • [4] Comparison of PD-L1 expression before and after neoadjuvant chemoradiation or chemotherapy in stage III non-small cell lung cancer (NSCLC)
    Koenig, D.
    Prince, S. Savic
    Trachsel, B.
    Hayoz, S.
    Pless, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S1376 - S1376
  • [5] SAKK 16114: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)-A multicenter single-arm phase II trial.
    Rothschild, Sacha
    Zippelius, Alfred
    Savic, Spasenija
    Gonzalez, Michel
    Weder, Walter
    Xyrafas, Alexandros
    Rusterholz, Corinne
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC): A multicenter single-arm phase II trial
    Rothschild, S. I.
    Zippelius, A.
    Prince, S. Savic
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S70 - S70
  • [7] SAKK 16/14-anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage ILIA (N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial
    Rothschild, S. I.
    Zippelius, A.
    Prince, S. Savic
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S112 - S112
  • [8] SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)-A multicenter single-arm phase II trial
    Rothschild, Sacha
    Zippelius, Alfred
    Savic, Spasenija
    Gonzalez, Michel
    Weder, Walter
    Xyrafas, Alexandros
    Rusterholz, Corinne
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
    Lin, Y-B
    Long, H.
    Chen, Y-H
    Zhai, W-Y
    Wang, Y-Z
    Rao, B-Y
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S287 - S287
  • [10] SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
    Rothschild, Sacha, I
    Zippelius, Alfred
    Eboulet, Eric, I
    Prince, Spasenija Savic
    Betticher, Daniel
    Bettini, Adrienne
    Frueh, Martin
    Joerger, Markus
    Lardinois, Didier
    Gelpke, Hans
    Mauti, Laetitia A.
    Britschgi, Christian
    Weder, Walter
    Peters, Solange
    Mark, Michael
    Cathomas, Richard
    Ochsenbein, Adrian F.
    Janthur, Wolf-Dieter
    Waibel, Christine
    Mach, Nicolas
    Froesch, Patrizia
    Buess, Martin
    Bohanes, Pierre
    Godar, Gilles
    Rusterholz, Corinne
    Gonzalez, Michel
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2872 - +
12345